ZB014
/ Zenas BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 16, 2026
A new, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) is progressing toward clinical development
(GlobeNewswire)
- "Developed using half-life extension technology for monoclonal antibodies, and based on preclinical study results, ZB014 has the potential to provide the clinical activity and safety profile observed with obexelimab while offering a once-monthly dosing schedule."
New molecule • Immunology
1 to 1
Of
1
Go to page
1